Literature DB >> 17045937

Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure.

Francesco Grigioni1, Luciano Potena, Nazzareno Galiè, Francesco Fallani, Mauro Bigliardi, Fabio Coccolo, Gaia Magnani, Alessandra Manes, Andrea Barbieri, Alessandro Fucili, Carlo Magelli, Angelo Branzi.   

Abstract

BACKGROUND: It is unknown whether time-related changes of pulmonary hypertension (PH) have prognostic relevance in severe chronic heart failure (CHF).
METHODS: All CHF patients referred for follow-up from 1996 through 2003 were screened for this study. Eligibility depended on availability of a concomitant clinical, laboratory, electrocardiographic (ECG), echocardiographic and right-heart catheterization (RHC) assessment at index evaluation, as well as absence of pre-capillary PH.
RESULTS: One hundred ninety-six patients (age 54 +/- 9 years; 27% women, 73% men; 50% in New York Heart Association [NYHA] Class III or IV) were included. PH at index evaluation was an independent predictor of acute heart failure or cardiovascular death (AHF/CD), with adjusted risk ratio (RR) = 2.30, 95% confidence interval (CI) 1.42 to 3.73 and p < 0.001. A pre-study (> or =6 months) RHC was available for 174 of the 196 patients. Worsening of mean pulmonary artery pressure (mPAP) of > or =30% (a pre-specified cut-off corresponding to the 75th percentile of DeltamPAP%) provided prognostic information independent of all index-evaluation parameters (adjusted RR = 2.60, 95% CI 1.45 to 4.67, p = 0.001), and from time-related changes in the other hemodynamic parameters (p < or = 0.033).
CONCLUSIONS: PH retains independent prognostic significance even after adjusting for a large set of clinical/laboratory/instrumental parameters. Furthermore, serial measurements of mPAP seem to provide additional prognostic information as compared with a single assessment. These findings indicate that serial evaluations of PAP may help identify a sub-set of high-risk CHF patients deserving a particularly close follow-up to facilitate timely indications for non-pharmacologic strategies, including (when appropriate) heart transplantation.

Entities:  

Mesh:

Year:  2006        PMID: 17045937     DOI: 10.1016/j.healun.2006.06.015

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  32 in total

Review 1.  Soluble guanylate cyclase modulators in heart failure.

Authors:  Veselin Mitrovic; Ana Jovanovic; Stefan Lehinant
Journal:  Curr Heart Fail Rep       Date:  2011-03

2.  ECG-gated computed tomography to assess pulmonary capillary wedge pressure in pulmonary hypertension.

Authors:  Nancy Sauvage; Emilie Reymond; Adrien Jankowski; Marion Prieur; Christophe Pison; Hélène Bouvaist; Gilbert R Ferretti
Journal:  Eur Radiol       Date:  2013-06-09       Impact factor: 5.315

Review 3.  Right ventricular adaptation and failure in pulmonary arterial hypertension.

Authors:  John J Ryan; Jessica Huston; Shelby Kutty; Nathan D Hatton; Lindsay Bowman; Lian Tian; Julia E Herr; Amer M Johri; Stephen L Archer
Journal:  Can J Cardiol       Date:  2015-01-29       Impact factor: 5.223

4.  Gaps in the Heart Failure Guidelines.

Authors:  Bao Tran; Gregg C Fonarow
Journal:  Card Fail Rev       Date:  2015-04

Review 5.  Gaps in the Heart Failure Guidelines.

Authors:  Bao Tran; Gregg C Fonarow
Journal:  Eur Cardiol       Date:  2014-12

Review 6.  Complications of Cardiac Transplantation.

Authors:  Luciano Potena; Andreas Zuckermann; Francesco Barberini; Arezu Aliabadi-Zuckermann
Journal:  Curr Cardiol Rep       Date:  2018-07-10       Impact factor: 2.931

7.  Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers.

Authors:  Aaron W Trammell; Meredith E Pugh; John H Newman; Anna R Hemnes; Ivan M Robbins
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

8.  Pulmonary hypertension associated with heart failure with preserved ejection fraction: acute hemodynamic effects of inhaled iloprost.

Authors:  Nicole L Grossman; Christopher A Fiack; Janice M Weinberg; Denis V Rybin; Harrison W Farber
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

9.  Pulmonary pressures and death in heart failure: a community study.

Authors:  Francesca Bursi; Sheila M McNallan; Margaret M Redfield; Vuyisile T Nkomo; Carolyn S P Lam; Susan A Weston; Ruoxiang Jiang; Véronique L Roger
Journal:  J Am Coll Cardiol       Date:  2012-01-17       Impact factor: 24.094

10.  Arterial-ventricular and interventricular interaction in isolated post-capillary and combined pulmonary hypertension in severe mitral stenosis.

Authors:  Ashwin Venkateshvaran; Srikanth Sola; Satish Chandra Govind; Pravat Kumar Dash; Sagar Vyavahare; Lars H Lund; Bé la Merkely; Anikó Ilona Nagy; Aristomenis Manouras
Journal:  Eur J Appl Physiol       Date:  2016-05-19       Impact factor: 3.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.